EA201300171A1 - Способы и композиции для терапии рака печени - Google Patents

Способы и композиции для терапии рака печени

Info

Publication number
EA201300171A1
EA201300171A1 EA201300171A EA201300171A EA201300171A1 EA 201300171 A1 EA201300171 A1 EA 201300171A1 EA 201300171 A EA201300171 A EA 201300171A EA 201300171 A EA201300171 A EA 201300171A EA 201300171 A1 EA201300171 A1 EA 201300171A1
Authority
EA
Eurasian Patent Office
Prior art keywords
liver cancer
methods
compositions
cancer therapy
antiproastrin
Prior art date
Application number
EA201300171A
Other languages
English (en)
Other versions
EA028515B1 (ru
Inventor
Лейла Уу
Анн-Софи Дюме
Доминик Жубер
Фредерик Олланд
Original Assignee
Ле Лаборатуар Сервье
Инститю Насьональ Де Ля Сент Э Де Ля Решерш Медисаль (Инсерм)
Сантр Насьональ Де Ля Решерш Сьентифик (Снрс)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ле Лаборатуар Сервье, Инститю Насьональ Де Ля Сент Э Де Ля Решерш Медисаль (Инсерм), Сантр Насьональ Де Ля Решерш Сьентифик (Снрс) filed Critical Ле Лаборатуар Сервье
Publication of EA201300171A1 publication Critical patent/EA201300171A1/ru
Publication of EA028515B1 publication Critical patent/EA028515B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/595—Gastrins; Cholecystokinins [CCK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Заявка обеспечивает способы лечения рака печени и предотвращения рецидива рака печени с помощью антипрогастриновых антител, способы мониторинга эффективности лечения рака печени при использовании антипрогастриновой терапии и композиции, которые применяются для этого.
EA201300171A 2010-07-26 2011-07-22 Способы и композиции для терапии рака печени EA028515B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36785110P 2010-07-26 2010-07-26
US201161476204P 2011-04-15 2011-04-15
PCT/EP2011/062686 WO2012013609A1 (en) 2010-07-26 2011-07-22 Methods and compositions for liver cancer therapy

Publications (2)

Publication Number Publication Date
EA201300171A1 true EA201300171A1 (ru) 2013-07-30
EA028515B1 EA028515B1 (ru) 2017-11-30

Family

ID=45493809

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201790882A EA201790882A1 (ru) 2010-07-26 2011-07-22 Способы и композиции для терапии рака печени
EA201300171A EA028515B1 (ru) 2010-07-26 2011-07-22 Способы и композиции для терапии рака печени

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201790882A EA201790882A1 (ru) 2010-07-26 2011-07-22 Способы и композиции для терапии рака печени

Country Status (16)

Country Link
US (1) US10533050B2 (ru)
EP (1) EP2598531B1 (ru)
JP (1) JP5726305B2 (ru)
KR (1) KR101576174B1 (ru)
CN (1) CN103261224B (ru)
AR (1) AR082340A1 (ru)
AU (1) AU2011284908B2 (ru)
BR (1) BR112013002012A2 (ru)
CA (1) CA2806157C (ru)
EA (2) EA201790882A1 (ru)
ES (1) ES2871092T3 (ru)
NZ (1) NZ606195A (ru)
PL (1) PL2598531T3 (ru)
SG (2) SG10201703556YA (ru)
WO (1) WO2012013609A1 (ru)
ZA (1) ZA201300567B (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5644110B2 (ja) 2008-08-05 2014-12-24 東レ株式会社 癌の検出方法
KR101667319B1 (ko) 2008-08-05 2016-10-18 도레이 카부시키가이샤 암의 치료 및 예방용 의약 조성물
US8900817B2 (en) 2010-01-08 2014-12-02 Les Laboratories Servier Progastrin and liver pathologies
EP2532743B1 (en) 2010-02-04 2015-04-15 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
BR112014002616B1 (pt) 2011-08-04 2022-01-18 Toray Industries, Inc Método para detectar câncer pancreático
WO2013018894A1 (ja) 2011-08-04 2013-02-07 東レ株式会社 癌の治療及び／又は予防用医薬組成物
BR112014002619A2 (pt) 2011-08-04 2018-10-09 Toray Industries, Inc composição farmacêutica e método de tratamento e/ou prevenção de câncer pancreático e combinação farmacêutica
CA2864999C (en) 2012-02-21 2020-06-30 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
PL2818483T3 (pl) 2012-02-21 2018-01-31 Toray Industries Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi
PL2818482T3 (pl) 2012-02-21 2019-11-29 Toray Industries Kompozycja farmaceutyczna do leczenia nowotworu
IN2014KN01716A (ru) 2012-02-21 2015-10-23 Toray Industries
CN104203281B (zh) 2012-03-30 2019-07-26 东丽株式会社 胆囊癌的治疗和/或预防用药物组合物
EP2832365B1 (en) * 2012-03-30 2017-11-01 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of liver cancer
KR102056654B1 (ko) 2012-07-19 2019-12-17 도레이 카부시키가이샤 암의 검출 방법
CN104471404B (zh) 2012-07-19 2017-03-01 东丽株式会社 癌的检测方法
TR201819812T4 (tr) 2013-08-09 2019-01-21 Toray Industries Kanserin Tedavisi Ve/Veya Önlenmesi Amacına Yönelik Farmasötik Bileşim
KR20170054459A (ko) * 2014-09-10 2017-05-17 더블 본드 파마슈티컬스 에이비 친수성 약물의 표적 전달 방법
EP3023884A1 (en) * 2014-11-21 2016-05-25 Thomson Licensing Method and apparatus for generating fingerprint of an audio signal
CN114705858A (zh) 2015-12-31 2022-07-05 Syncerus有限责任公司 用于评估癌症发生的风险的组合物和方法
US20190011449A1 (en) 2015-12-31 2019-01-10 Progastrine Et Cancers S.À R.L. Compositions and methods for detecting and treating gastric cancer
JP7018885B2 (ja) 2015-12-31 2022-02-14 プロガストリン、エ、カンセル、エス、アー エル、エル 食道癌の検出および治療のための組成物および方法
EA037015B1 (ru) 2015-12-31 2021-01-27 Прогастрин Э Кансер С.А Р.Л. Применение и способ для профилактики или лечения рака яичников с использованием композиции, содержащей прогастринсвязывающее антитело
KR102351556B1 (ko) 2017-03-30 2022-01-14 프로가스트린 에 캔서스 에스.에이 알.엘. 프로가스트린 결합 분자를 사용하는 전립선암의 검출 및 치료를 위한 조성물 및 방법
KR102616819B1 (ko) 2017-03-30 2023-12-21 프로가스트린 에 캔서스 에스.에이 알.엘. 폐암을 치료하기 위한 조성물 및 방법
WO2019110662A1 (en) * 2017-12-05 2019-06-13 Progastrine Et Cancers S.À R.L. Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
CN112004560A (zh) 2017-12-08 2020-11-27 Ecs生物识别***有限公司 癌症诊断中的放射性标记的前胃液素
TW201940881A (zh) 2018-01-26 2019-10-16 瑞士商Ｅｃｓ前胃泌激素公司 在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術
EP3759492A1 (en) * 2018-02-27 2021-01-06 ECS-Progastrin SA Progastrin as a biomarker for immunotherapy
AU2020358101A1 (en) * 2019-10-02 2022-04-28 Alamab Therapeutics, Inc. Anto-connexin antibody formulations

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
DE69935977T2 (de) * 1998-05-15 2008-01-10 Receptor Biologix, Inc., Palo Alto Vorbeugung und Behandlung von Hypergastrinämie
CA2450898A1 (en) * 2001-07-09 2003-01-23 Aphton Corporation Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus
US20080057519A1 (en) * 2003-06-02 2008-03-06 Mcwhirter John Cell Surface Protein Associated with Human Chronic Lymphocytic Leukemia
JP2008513536A (ja) * 2004-09-22 2008-05-01 レセプター バイオロジックス インコーポレイテッド プロガストリンに対するモノクローナル抗体
CN101460196A (zh) * 2006-05-22 2009-06-17 国立医学与健康研究所 在结肠癌治疗中的前胃泌素抑制剂
WO2008076454A1 (en) 2006-12-19 2008-06-26 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
SG10201704933PA (en) * 2009-10-16 2017-07-28 Inst Nat De La Sante Et De La Rech Medicale (Inserm) Monoclonal antibodies to progastrin and their uses
US8900817B2 (en) * 2010-01-08 2014-12-02 Les Laboratories Servier Progastrin and liver pathologies
US9487582B2 (en) * 2010-01-08 2016-11-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for treating pancreatic cancer
US9217032B2 (en) * 2010-01-08 2015-12-22 Les Laboratoires Servier Methods for treating colorectal cancer
KR101570404B1 (ko) * 2010-03-24 2015-11-20 르 라보레또레 쎄르비에르 결장직장암 및 위창자암의 예방

Also Published As

Publication number Publication date
PL2598531T3 (pl) 2021-08-30
ES2871092T3 (es) 2021-10-28
NZ606195A (en) 2015-02-27
EA028515B1 (ru) 2017-11-30
SG10201703556YA (en) 2017-06-29
EA201790882A1 (ru) 2017-08-31
JP5726305B2 (ja) 2015-05-27
ZA201300567B (en) 2014-03-26
AR082340A1 (es) 2012-11-28
SG187544A1 (en) 2013-03-28
WO2012013609A1 (en) 2012-02-02
EP2598531B1 (en) 2020-12-30
CN103261224A (zh) 2013-08-21
EP2598531A1 (en) 2013-06-05
CN103261224B (zh) 2015-10-07
KR101576174B1 (ko) 2015-12-09
BR112013002012A2 (pt) 2019-08-27
AU2011284908A1 (en) 2013-02-07
JP2013533277A (ja) 2013-08-22
US10533050B2 (en) 2020-01-14
US20120020961A1 (en) 2012-01-26
KR20130083438A (ko) 2013-07-22
AU2011284908B2 (en) 2015-05-21
CA2806157A1 (en) 2012-02-02
CA2806157C (en) 2016-11-22

Similar Documents

Publication Publication Date Title
EA201300171A1 (ru) Способы и композиции для терапии рака печени
EA201890754A1 (ru) Соединения и способы их применения
EA201590997A1 (ru) Соединения и способы их применения
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
WO2018112365A3 (en) Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
EA201792191A1 (ru) Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
EA200900819A1 (ru) Хиназолины для ингибирования pdk1
EA201201000A1 (ru) Способы лечения колоректального рака
EA201991772A1 (ru) Способ лечения рака предстательной железы с использованием комбинации на основе модулятора андрогенного рецептора
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
EA201591599A1 (ru) Ингибиторы ido
EA201690027A1 (ru) Ингибиторы ido
EA201370071A1 (ru) Способы и композиции для лечения рака легких
MX2016006726A (es) Composiciones que comprenden anticuerpos anti-molecula de adhesion celular relacionada con antigeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cancer.
EA201291031A1 (ru) Способ лечения ожирения с применением антиоксидантных модуляторов воспаления
EA201690152A1 (ru) Ингибиторы ido
EA201591823A1 (ru) Ингибиторы ido
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
EA201390756A1 (ru) Модулирующие nk-клетки терапии и способы для лечения гематологических злокачественных заболеваний
EA201692483A1 (ru) Ингибиторы гистоновой метилазы
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
EA201170288A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
EA201791736A1 (ru) Комбинированная терапия для лечения рака

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM